期刊
KIDNEY INTERNATIONAL
卷 94, 期 6, 页码 1040-1042出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.kint.2018.07.029
关键词
-
资金
- NIDDK NIH HHS [R37 DK039773] Funding Source: Medline
Kidney organoids, derived from human pluripotent stem cells, have the potential to greatly facilitate drug development. Borestrom et al. have used CRISPR/Cas9 to create kidney fluorescent lineage markers for SIX2 and NPHS1 to monitor the differentiation process to tubular and glomerular structures and optimize maturity. The convergence of personalized kidney organoids with genome editing and single-cell sequencing technology hold great promise to result in better insight to disease, better human cell disease models, more predictive toxicology, and potentially clinical trials in a dish. Copyright (C) 2018, Published by Elsevier, Inc., on behalf of the International Society of Nephrology.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据